Schedio Acquires Micromacinazione to Lead Pharma Micronization

Schedio has acquired Micromacinazione for an undisclosed amount, marking a significant expansion in the pharmaceutical services sector.

Micromacinazione specializes in particle size reduction, powder classification, and analytical services, primarily for the pharmaceutical industry.

The company serves a diverse clientele, including small biotechs, Big Pharma, CDMOs, and functional excipient companies, focusing on enhancing the dissolution and bioavailability of Active Pharmaceutical Ingredients (APIs) through its advanced milling and micronization processes.

Micromacinazione is recognized as North America's largest independent pharmaceutical micronization business, offering high-turn feasibility studies and robust high containment infrastructure for highly potent compounds, including cytotoxics.

Its comprehensive solutions support small molecule APIs, HPAPIs, functional excipients, NCEs, and generics across all phases of development, from discovery through commercial launch and generic production, operating from a significant US-based footprint.

This acquisition strategically positions Schedio to enhance its capabilities within the pharmaceutical supply chain.

By integrating Micromacinazione's specialized expertise in micronization and high-potency API handling, Schedio is expected to gain a leading edge in critical API development and manufacturing services.

The synergy lies in leveraging Micromacinazione's established market leadership, scientific know-how, and extensive operational capacity to offer more comprehensive and integrated solutions to the pharmaceutical sector.

The combined entity is anticipated to deliver an expanded portfolio of services, reinforcing its commitment to supporting pharmaceutical innovation and production.

This move is set to strengthen its market presence and foster greater efficiency in bringing new and improved drug formulations to market, benefiting clients seeking advanced particle engineering and containment solutions.